{"DataElement":{"publicId":"8178069","version":"1","preferredName":"Transplant-Associated Thrombotic Microangiopathy Occurrence Yes No Indicator","preferredDefinition":"The indication of whether or not transplant-associated thrombotic microangiopathy occurred.","longName":"TA_TMA_OCCUR_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"8178068","version":"1","preferredName":"Transplant-Associated Thrombotic Microangiopathy Occurrence","preferredDefinition":"Thrombotic microangiopathy that presents in some patients undergoing hematopoietic stem cell transplantation (HSCT). Though similar in presentation to thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS), transplant-associated thrombotic microangiopathy (TA-TMA) is a distinct disorder. Several risk factors may be associated with TA-TMA, including high-dose chemotherapy, radiation therapy, HLA mismatch, use of calcineurin inhibitors, acute graft-versus-host disease (GVHD), and infections._An instance of something happening, such as an event or incident.","longName":"7433879v1.0:2234856v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7433879","version":"1","preferredName":"Transplant-Associated Thrombotic Microangiopathy","preferredDefinition":"Thrombotic microangiopathy that presents in some patients undergoing hematopoietic stem cell transplantation (HSCT). Though similar in presentation to thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS), transplant-associated thrombotic microangiopathy (TA-TMA) is a distinct disorder. Several risk factors may be associated with TA-TMA, including high-dose chemotherapy, radiation therapy, HLA mismatch, use of calcineurin inhibitors, acute graft-versus-host disease (GVHD), and infections.","longName":"C174553","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplant-Associated Thrombotic Microangiopathy","conceptCode":"C174553","definition":"Thrombotic microangiopathy that presents in some patients undergoing hematopoietic stem cell transplantation (HSCT). Though similar in presentation to thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS), transplant-associated thrombotic microangiopathy (TA-TMA) is a distinct disorder. Several risk factors may be associated with TA-TMA, including high-dose chemotherapy, radiation therapy, HLA mismatch, use of calcineurin inhibitors, acute graft-versus-host disease (GVHD), and infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0016DB7-D2D0-2205-E053-4EBD850A7507","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234856","version":"1","preferredName":"Occurrence","preferredDefinition":"Occurrence; an instance of something happening.","longName":"C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-72B8-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDB9809F-A874-53E6-E053-4EBD850A30C6","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-28","modifiedBy":"CLOHNES","dateModified":"2022-09-07","changeDescription":null,"administrativeNotes":"9/7/22 Released DEC per AK for COG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TATMAIND","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"Did transplant-associated thr","type":"Preferred Question Text","description":"Did transplant-associated thrombotic microangiopathy occur?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Did patient experience Transplant-associated thrombotic microangiopathy (TA-TMA) during this reporting period?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDB98A76-E94D-53F1-E053-4EBD850A4E67","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-28","modifiedBy":"CLOHNES","dateModified":"2022-09-07","changeDescription":null,"administrativeNotes":"9/7/22 Released CDE per AK for COG cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}